Greenwich Lifesciences Inc Cash Flow Conversion Efficiency
Greenwich Lifesciences Inc cash flow conversion efficiency. Based on the latest financial reports, Greenwich Lifesciences Inc (GLSI) has a cash flow conversion efficiency ratio of -0.622x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.94 Million) by net assets ($3.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Greenwich Lifesciences Inc (2017–2025)
Cash flow conversion efficiency of Greenwich Lifesciences Inc from 2017 to 2025. This chart illustrates how Greenwich Lifesciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Greenwich Lifesciences Inc (GLSI) share price today for real-time trading data and today's change.
Greenwich Lifesciences Inc Cash Flow Conversion Ratio Explained
Greenwich Lifesciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Greenwich Lifesciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Greenwich Lifesciences Inc ranked by their cash flow conversion efficiency. Also see Greenwich Lifesciences Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yorkville International Capital Corp. Class A Ordinary Shares
NASDAQ:YICC
|
N/A |
|
Aspo Oyj
HE:ASPO
|
0.005x |
|
Tanco Holdings Bhd
KLSE:2429
|
-0.046x |
|
Quantum eMotion Corp.
V:QNC
|
-0.051x |
|
Bank of Zhengzhou Co. Ltd
F:3BZ
|
-0.076x |
|
Biodesix Inc
NASDAQ:BDSX
|
-0.171x |
|
Kepler Weber S.A
SA:KEPL3
|
0.071x |
|
Biostar Microtech International Corp
TW:2399
|
-0.047x |
Annual Cash Flow Conversion Efficiency for Greenwich Lifesciences Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Greenwich Lifesciences Inc from 2017 to 2025. Review cash generation quality of Greenwich Lifesciences Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $353.22K | $-9.91 Million | -28.066x | -250.95% |
| 2024-12-31 | $908.63K | $-7.27 Million | -7.997x | -727.11% |
| 2023-12-31 | $6.70 Million | $-6.48 Million | -0.967x | -106.07% |
| 2022-12-31 | $13.21 Million | $-6.20 Million | -0.469x | -193.35% |
| 2021-12-31 | $26.83 Million | $-4.29 Million | -0.160x | -283.31% |
| 2020-12-31 | $27.63 Million | $-1.15 Million | -0.042x | -119.21% |
| 2019-12-31 | $-1.35 Million | $-293.27K | 0.217x | +1811.88% |
| 2018-12-31 | $-10.12 Million | $-114.95K | 0.011x | -19.82% |
| 2017-12-31 | $-8.53 Million | $-120.85K | 0.014x | -- |
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Ph… Read more